SB 1639, the American Innovation and Jobs Act, would revise federal tax treatment of research and experimental expenditures to restore immediate expensing under Internal Revenue Code section 174. Under current law, many research and development costs must be capitalized and amortized; this bill would again allow taxpayers to deduct qualifying research or experimental expenditures in the year they are paid or incurred, while preserving an optional amortization election for certain costs over at least 60 months. The bill also makes conforming changes to the research credit rules so they align with the restored expensing treatment.
The bill further expands and makes more accessible the research credit for startups and small businesses. It increases the refundable payroll tax credit cap for eligible new businesses on a phased schedule from $500,000 for tax years beginning after 2024 up to $750,000 for tax years beginning after 2034, extends the startup eligibility window from 5 to 8 years, and broadens the gross receipts thresholds used to qualify. It also raises the research credit rate for qualified small businesses and provides alternative methods for calculating the credit when a business has years with no qualified research expenses. Most provisions generally apply to tax years beginning after December 31, 2021 or after December 31, 2024, depending on the section.
In practical terms, the bill would reduce federal tax liability for companies conducting research and development, especially startups, small firms, and businesses with significant R&D spending. It would affect Internal Revenue Code sections 174, 41, 280C, and related payroll tax credit provisions, and would likely be most relevant to technology, manufacturing, life sciences, and other innovation-intensive industries. By restoring immediate deduction of research costs, the bill would also change how businesses recover R&D investments for tax purposes.
The overall sentiment reflected in the bill’s sponsorship is strongly supportive and bipartisan. The measure was introduced by a large bipartisan group of senators, suggesting broad interest in encouraging domestic innovation and easing the tax burden on research activity. No committee transcript or vote record is provided, so there is no recorded floor or committee debate in the materials supplied.
The main point of contention likely concerns fiscal cost and policy design rather than the general goal of supporting research. Restoring immediate expensing and expanding refundable credits would reduce federal revenue, and some policymakers may question whether the benefits are targeted appropriately or whether the changes should be temporary or offset. Another possible issue is that the bill applies some changes retroactively to tax years beginning after 2021, which could raise administrative and budgetary concerns for the Treasury and taxpayers.
The bill would amend the Internal Revenue Code to restore immediate deduction of research and experimental expenditures under section 174, expand and modify the research credit under section 41, adjust the interaction between the credit and deductible expenses under section 280C, and revise related payroll tax credit rules for qualified small businesses. It would directly affect taxpayers with R&D costs, especially startups and small businesses, by lowering after-tax research costs and increasing refundable credit availability.
The bill appears to have favorable bipartisan support, as shown by its many Senate cosponsors from both parties. The text frames the measure as pro-innovation and pro-jobs, and there is no provided committee or vote record indicating organized opposition in the materials. Based on the sponsorship pattern alone, the general sentiment is supportive, with the policy goal of encouraging research and startup growth.
The likely points of contention are the revenue impact, the retroactive effective date for some provisions, and whether the expanded benefits are too broad or insufficiently targeted. Supporters would emphasize restoring immediate R&D expensing and helping startups access refundable credits; critics may focus on federal cost, complexity, and whether the changes favor certain industries or firms with existing tax capacity. No specific objections are recorded in the provided transcripts or votes.